TY - JOUR T1 - Poor correlation between antibody titers and neutralizing activity in sera from SARS-CoV-2 infected subjects JF - medRxiv DO - 10.1101/2020.07.10.20150375 SP - 2020.07.10.20150375 AU - Elena Criscuolo AU - Roberta A. Diotti AU - Marta Strollo AU - Serena Rolla AU - Alessandro Ambrosi AU - Massimo Locatelli AU - Roberto Burioni AU - Nicasio Mancini AU - Massimo Clementi AU - Nicola Clementi Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/07/11/2020.07.10.20150375.abstract N2 - Plenty of serologic tests for SARS-CoV-2 have been developed so far, thus documenting the importance of evaluating the relevant features of the immune response to this viral agent. The performance of these assays is currently under investigation. Amongst them, LIAISONĀ® SARS-CoV-2 S1/S2 IgG by DiaSorin and Elecsys Anti-SARS-CoV-2 cobasĀ® by Roche are currently used by laboratory medicine hospital departments in Italy and many other countries. In the present study, we have firstly compared two serologic tests on serum samples collected at two different time points from forty-six laboratory-confirmed COVID-19 subjects. Secondly, eighty-five negative serum samples collected before the SARS-CoV-2 pandemic were analyzed. Thirdly, possible correlations between antibody levels and the resulting neutralizing activity against a clinical isolate of SARS-CoV-2 were evaluated. Results revealed that both tests are endowed with low sensitivity on the day of hospital admission, which increased to 97.8 and 100% for samples collected after 15 days for DiaSorin and Roche tests, respectively. The specificity of the two tests ranges from 96.5 to 100%, respectively. Importantly, a poor direct correlation between antibody titers and neutralizing activity levels was evidenced in the present study.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04318366Funding StatementNo funding to declare.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was reviewed and approved by San Raffaele Hospital IRB in the 63 COVID-19 Biobanking project COVID-BioB N. CE: 34/int/2020 19/ March/2020 64 ClinicalTrials.gov Identifier: NCT04318366.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request. ER -